Joint ENGOT and GOG Foundation requirements for trials with industry partners
Vergote I (1), Coleman RL (2), Pignata S (3), Bookman MA (4), Marth C (5), Herzog TJ (6), Gonzalez-Martin A (7), Copeland LJ (8); European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation Inc..
(1) ENGOT/BGOG and University Hospital Leuven, Gynaecological Oncology, Leuven Cancer Institute, Herestraat 49, 3000 Leuven, Belgium, European Union. Electronic address: Ignace.email@example.com.
(2) GOG-F and Gynecologic Oncology & Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
(3) ENGOT/MITO Istituto Nazionale Tumori IRCCS Fondazione Pascale Napoli, Italy.
(4) GOG-F and Gynecologic Oncology Therapeutics, Kaiser Permanente San Francisco, San Francisco, USA.
(5) ENGOT/A-AGO and Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.
(6) GOG-F and Gynecologic Oncology, University of Cincinnati, Cincinnati, Ohio, USA.
(7) ENGOT/GEICO and Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain.
(8) GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA.
The European Network of Gynaecological Oncological Trial Groups (ENGOT) is a research network of the European Society of Gynaecological Oncology (ESGO), which was founded in 2007 and published earlier its requirements for studies with industry and a roadmap for ENGOT studies [, , ].
The GOG Foundation, Inc. (GOG-F) is non-profit 501(c)  corporation based in the District of Columbia, USA, which serves as the organizational body for National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-funded NRG Oncology and GOG-Partners (GOG-F industry) trials.
The legacy Gynecologic Oncology Group cooperative group was established in 1969 and held its first official meeting in 1970 under the guidance and support of the U.S. NCI . In 2010, the NCI announced its intention to restructure and consolidate the cooperative group system for federally funded research following a study by the Institute of Medicine (IOM) highlighting efficiencies and cost reduction.
This process led to the consolidated group, NRG Oncology Foundation, Inc. (“NRG Oncology”), formed in 2011 by the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG) to conduct federally-funded government research; NRG Oncology Philadelphia East is the branch of this group, which houses the legacy GOG cooperative group.
To avoid confusion of the new Groups at that time, the corporate name “Gynecologic Oncology Group Inc.” was changed to The GOG Foundation, Inc. (GOG-F), and its industry-sponsored trials are conducted under the brand name of “GOG-Partners.” The GOG-Foundation, Inc. is the non-profit organization collectively bridging NRG Oncology and GOG-Partners.
The GOG Foundation has designated GOG Partners to oversee non-CTEP funded investigative ventures, including collaborative functions with ENGOT.
CITA DEL ARTÍCULO Gynecol Oncol. 2019 Aug;154(2):255-258. doi: 10.1016/j.ygyno.2019.04.677